Bolt Biotherapeutics (BOLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bolt Biotherapeutics (BOLT) has a cash flow conversion efficiency ratio of -0.270x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.16 Million) by net assets ($26.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BOLT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Bolt Biotherapeutics - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Bolt Biotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bolt Biotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bolt Biotherapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Libero Copper Corp
V:LBC
|
-0.737x |
|
Rostra AG
F:3330
|
N/A |
|
Cloudastructure, Inc. Class A Common Stock
NASDAQ:CSAI
|
-0.141x |
|
Urban Logistics Reit PLC
LSE:SHED
|
0.028x |
|
North Arrow Minerals Inc
V:NAR
|
-0.011x |
|
Star Minerals Ltd
AU:SMS
|
-0.100x |
|
SOLUTIANCE AG NA O.N.
F:SLSA
|
N/A |
|
XTL Biopharmaceuticals Ltd ADR
NASDAQ:XTLB
|
-0.369x |
Annual Cash Flow Conversion Efficiency for Bolt Biotherapeutics (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bolt Biotherapeutics from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see BOLT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.50 Million | $-39.85 Million | -1.503x | -40.31% |
| 2024-12-31 | $57.20 Million | $-61.29 Million | -1.072x | -73.76% |
| 2023-12-31 | $112.74 Million | $-69.53 Million | -0.617x | -38.25% |
| 2022-12-31 | $171.51 Million | $-76.50 Million | -0.446x | -95.51% |
| 2021-12-31 | $250.12 Million | $-57.07 Million | -0.228x | -150.61% |
| 2020-12-31 | $-104.95 Million | $-47.31 Million | 0.451x | -21.55% |
| 2019-12-31 | $-45.85 Million | $-26.34 Million | 0.575x | -7.20% |
| 2018-12-31 | $-15.94 Million | $-9.87 Million | 0.619x | -- |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agon… Read more